Mitigation of radiation injury by selective stimulation of the LPA 2 receptor

Gyöngyi N. Kiss, Sue Lee, James I. Fells, Jianxiong Liu, William J. Valentine, Yuko Fujiwara, Karin Emmons Thompson, Charles Yates, Balázs Sümegi, Gabor Tigyi

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Due to its antiapoptotic action, derivatives of the lipid mediator lysophosphatidic acid (LPA) provide potential therapeutic utility in diseases associated with programmed cell death. Apoptosis is one of the major pathophysiological processes elicited by radiation injury to the organism. Consequently, therapeutic explorations applying compounds that mimic the antiapoptotic action of LPA have begun. Here we present a brief account of our decade-long drug discovery effort aimed at developing LPA mimics with a special focus on specific agonists of the LPA2 receptor subtype, which was found to be highly effective in protecting cells from apoptosis. We describe new evidence that 2-((3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)thio) benzoic acid (GRI977143), a prototypic nonlipid agonist specific to the LPA 2 receptor subtype, rescues apoptotically condemned cells in vitro and in vivo from injury caused by high-dose γ-irradiation. GRI977143 shows the features of a radiomitigator because it is effective in rescuing the lives of mice from deadly levels of radiation when administered 24 h after radiation exposure. Our findings suggest that by specifically activating LPA2 receptors GRI977143 activates the ERK1/2 prosurvival pathway, effectively reduces Bax translocation to the mitochondrion, attenuates the activation of initiator and effector caspases, reduces DNA fragmentation, and inhibits PARP-1 cleavage associated with γ-irradiation-induced apoptosis. GRI977143 also inhibits bystander apoptosis elicited by soluble proapoptotic mediators produced by irradiated cells. Thus, GRI977143 can serve as a prototype scaffold for lead optimization paving the way to more potent analogs amenable for therapeutic exploration. This article is part of a Special Issue entitled Advances in Lysophospholipid Research.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalBiochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Volume1831
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Lysophosphatidic Acid Receptors
Radiation Injuries
Apoptosis
Initiator Caspases
Effector Caspases
Lysophospholipids
Benzoic Acid
MAP Kinase Signaling System
DNA Fragmentation
Drug Discovery
Mitochondria
Cell Death
Therapeutics
Radiation
Lipids
Wounds and Injuries
Research
lysophosphatidic acid

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cell Biology

Cite this

Mitigation of radiation injury by selective stimulation of the LPA 2 receptor. / Kiss, Gyöngyi N.; Lee, Sue; Fells, James I.; Liu, Jianxiong; Valentine, William J.; Fujiwara, Yuko; Thompson, Karin Emmons; Yates, Charles; Sümegi, Balázs; Tigyi, Gabor.

In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, Vol. 1831, No. 1, 01.01.2013, p. 117-125.

Research output: Contribution to journalReview article

Kiss, Gyöngyi N. ; Lee, Sue ; Fells, James I. ; Liu, Jianxiong ; Valentine, William J. ; Fujiwara, Yuko ; Thompson, Karin Emmons ; Yates, Charles ; Sümegi, Balázs ; Tigyi, Gabor. / Mitigation of radiation injury by selective stimulation of the LPA 2 receptor. In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids. 2013 ; Vol. 1831, No. 1. pp. 117-125.
@article{48a549c92f9c4c95903eb13ca99220a4,
title = "Mitigation of radiation injury by selective stimulation of the LPA 2 receptor",
abstract = "Due to its antiapoptotic action, derivatives of the lipid mediator lysophosphatidic acid (LPA) provide potential therapeutic utility in diseases associated with programmed cell death. Apoptosis is one of the major pathophysiological processes elicited by radiation injury to the organism. Consequently, therapeutic explorations applying compounds that mimic the antiapoptotic action of LPA have begun. Here we present a brief account of our decade-long drug discovery effort aimed at developing LPA mimics with a special focus on specific agonists of the LPA2 receptor subtype, which was found to be highly effective in protecting cells from apoptosis. We describe new evidence that 2-((3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)thio) benzoic acid (GRI977143), a prototypic nonlipid agonist specific to the LPA 2 receptor subtype, rescues apoptotically condemned cells in vitro and in vivo from injury caused by high-dose γ-irradiation. GRI977143 shows the features of a radiomitigator because it is effective in rescuing the lives of mice from deadly levels of radiation when administered 24 h after radiation exposure. Our findings suggest that by specifically activating LPA2 receptors GRI977143 activates the ERK1/2 prosurvival pathway, effectively reduces Bax translocation to the mitochondrion, attenuates the activation of initiator and effector caspases, reduces DNA fragmentation, and inhibits PARP-1 cleavage associated with γ-irradiation-induced apoptosis. GRI977143 also inhibits bystander apoptosis elicited by soluble proapoptotic mediators produced by irradiated cells. Thus, GRI977143 can serve as a prototype scaffold for lead optimization paving the way to more potent analogs amenable for therapeutic exploration. This article is part of a Special Issue entitled Advances in Lysophospholipid Research.",
author = "Kiss, {Gy{\"o}ngyi N.} and Sue Lee and Fells, {James I.} and Jianxiong Liu and Valentine, {William J.} and Yuko Fujiwara and Thompson, {Karin Emmons} and Charles Yates and Bal{\'a}zs S{\"u}megi and Gabor Tigyi",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.bbalip.2012.08.020",
language = "English (US)",
volume = "1831",
pages = "117--125",
journal = "Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids",
issn = "1388-1981",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Mitigation of radiation injury by selective stimulation of the LPA 2 receptor

AU - Kiss, Gyöngyi N.

AU - Lee, Sue

AU - Fells, James I.

AU - Liu, Jianxiong

AU - Valentine, William J.

AU - Fujiwara, Yuko

AU - Thompson, Karin Emmons

AU - Yates, Charles

AU - Sümegi, Balázs

AU - Tigyi, Gabor

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Due to its antiapoptotic action, derivatives of the lipid mediator lysophosphatidic acid (LPA) provide potential therapeutic utility in diseases associated with programmed cell death. Apoptosis is one of the major pathophysiological processes elicited by radiation injury to the organism. Consequently, therapeutic explorations applying compounds that mimic the antiapoptotic action of LPA have begun. Here we present a brief account of our decade-long drug discovery effort aimed at developing LPA mimics with a special focus on specific agonists of the LPA2 receptor subtype, which was found to be highly effective in protecting cells from apoptosis. We describe new evidence that 2-((3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)thio) benzoic acid (GRI977143), a prototypic nonlipid agonist specific to the LPA 2 receptor subtype, rescues apoptotically condemned cells in vitro and in vivo from injury caused by high-dose γ-irradiation. GRI977143 shows the features of a radiomitigator because it is effective in rescuing the lives of mice from deadly levels of radiation when administered 24 h after radiation exposure. Our findings suggest that by specifically activating LPA2 receptors GRI977143 activates the ERK1/2 prosurvival pathway, effectively reduces Bax translocation to the mitochondrion, attenuates the activation of initiator and effector caspases, reduces DNA fragmentation, and inhibits PARP-1 cleavage associated with γ-irradiation-induced apoptosis. GRI977143 also inhibits bystander apoptosis elicited by soluble proapoptotic mediators produced by irradiated cells. Thus, GRI977143 can serve as a prototype scaffold for lead optimization paving the way to more potent analogs amenable for therapeutic exploration. This article is part of a Special Issue entitled Advances in Lysophospholipid Research.

AB - Due to its antiapoptotic action, derivatives of the lipid mediator lysophosphatidic acid (LPA) provide potential therapeutic utility in diseases associated with programmed cell death. Apoptosis is one of the major pathophysiological processes elicited by radiation injury to the organism. Consequently, therapeutic explorations applying compounds that mimic the antiapoptotic action of LPA have begun. Here we present a brief account of our decade-long drug discovery effort aimed at developing LPA mimics with a special focus on specific agonists of the LPA2 receptor subtype, which was found to be highly effective in protecting cells from apoptosis. We describe new evidence that 2-((3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)thio) benzoic acid (GRI977143), a prototypic nonlipid agonist specific to the LPA 2 receptor subtype, rescues apoptotically condemned cells in vitro and in vivo from injury caused by high-dose γ-irradiation. GRI977143 shows the features of a radiomitigator because it is effective in rescuing the lives of mice from deadly levels of radiation when administered 24 h after radiation exposure. Our findings suggest that by specifically activating LPA2 receptors GRI977143 activates the ERK1/2 prosurvival pathway, effectively reduces Bax translocation to the mitochondrion, attenuates the activation of initiator and effector caspases, reduces DNA fragmentation, and inhibits PARP-1 cleavage associated with γ-irradiation-induced apoptosis. GRI977143 also inhibits bystander apoptosis elicited by soluble proapoptotic mediators produced by irradiated cells. Thus, GRI977143 can serve as a prototype scaffold for lead optimization paving the way to more potent analogs amenable for therapeutic exploration. This article is part of a Special Issue entitled Advances in Lysophospholipid Research.

UR - http://www.scopus.com/inward/record.url?scp=84868529772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868529772&partnerID=8YFLogxK

U2 - 10.1016/j.bbalip.2012.08.020

DO - 10.1016/j.bbalip.2012.08.020

M3 - Review article

VL - 1831

SP - 117

EP - 125

JO - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

JF - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

SN - 1388-1981

IS - 1

ER -